Skip to main content

Advertisement

Table 3 Primary endpoint analysis and therapeutic efficacy

From: Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia

  Treatment assignment Relapse control
AS + PQ AS-PYR + PQ DHA-PP + PQ
Subjects 60 60 60 41
Withdrawals 2 1 0 0
Relapses 10 9 7 32
Efficacy by incidence density
Person-years at risk 50.17 53.62 55.00 11.83
Relapse incidence density (attacks/person-yr) 0.20 0.17 0.13 2.71
Efficacy (%) against relapse (95 % CI) 92.2 (83.4 – 96.6) 93.5 (85.7 – 97.3) 95.0 (88.3 – 98.2) na
Efficacy by proportion relapse-free at 6 months
Relapses within 6 months 10 7 7 na
% free of recurrence at 6 Months 83 88 88 na
  1. AS artesunate, PQ primaquine, PYR pyronaridine, DHA-PP dihydroartemisinin-piperaquine